GAITHERSBURG, Md., Sept 9 (Reuters) - Merck & Co's cervical cancer vaccine is safe and effective for preventing genital warts in males ages 9 to 26, a U.S. advisory panel said on Wednesday.
The Gardasil vaccine has already been approved for girls and young women to prevent infection with the sexually transmitted human papillomavirus (HPV), which causes cervical cancer and genital warts.
A Food and Drug Administration (FDA) advisory panel voted 7-1 that Gardasil was safe for males. Seven panelists also said Merck's data showed the shot was effective, with one panel member abstaining from a vote.
Merck shares closed up 58 cents at $31.55 on Wednesday.
(Reporting by Lisa Richwine) Keywords: MERCK GARDASIL/ (lisa.richwine@thomsonreuters.com; +1 202 310-5691; Reuters Messaging: lisa.richwine.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
The Gardasil vaccine has already been approved for girls and young women to prevent infection with the sexually transmitted human papillomavirus (HPV), which causes cervical cancer and genital warts.
A Food and Drug Administration (FDA) advisory panel voted 7-1 that Gardasil was safe for males. Seven panelists also said Merck's data showed the shot was effective, with one panel member abstaining from a vote.
Merck shares closed up 58 cents at $31.55 on Wednesday.
(Reporting by Lisa Richwine) Keywords: MERCK GARDASIL/ (lisa.richwine@thomsonreuters.com; +1 202 310-5691; Reuters Messaging: lisa.richwine.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2009 AFX News
